## PATENT COOPERATION TREATY

## **PCT**

REC'D 0-2 MAR 2005

WIPO

PCT

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABIL

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference						
100952-1 WO	FOR FURTHER A	FOR FURTHER ACTION See Form PCT/IP				
International application No. International filing PCT/GB2004/000099 13.01.2004		(day/month/year)	Priority date (day/month/year) 16.01.2003			
International Patent Classification (IPC) or I	national classification and	IPC				
C07D211/70, C07D401/06, C07D4	05/06, C07D409/06, (	C07D417/06				
Applicant	_					
ASTRAZENECA AB						
			•			
Authority under Article 35 and tra	msmitted to the applica	nt according to Article 3	nis International Preliminary Examining 36.			
2. This REPORT consists of a total	•					
3. This report is also accompanied i						
a. Sent to the applicant and t						
sheets of the descript and/or sheets contain Administrative Instruc	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the					
☐ sheets which superse	de earlier sheets, but w	hich this Authority con	siders contain an amendment that goes			
beyond the disclosure Supplemental Box.	in the international ap	olication as filed, as ind	licated in item 4 of Box No. I and the			
b. (sent to the International E	Bureau only) a total of (	ndicate type and numb	per of electronic carrier(s)) , containing a			
Box Relating to Sequence	oles related thereto in (	Computer readable form	n only as indicated in the Symplemental			
Г						
4. This report contains indications re	elating to the following i	tems:				
☐ Box No. I Basis of the opt	inion					
☐ Box No. II Priority						
		ard to novelty, inventive	step and industrial applicability			
☐ Box No. IV Lack of unity of						
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain docume	ents cited	_				
	in the international app					
☐ Box No. VIII Certain observa	ations on the Internation	al application				
Date of submission of the demand		Date of completion of the	nis report			
			iio lopoli			
23.07.2004		28.02.2005				
Name and mailing address of the internation preliminary examining authority:	al	Authorized Officer	ALDES Pelanges			
European Patent Office - Gitse	chiner Str. 103		in the state of th			
D-10958 Berlin Tel. +49 30 25901 - 0		Hoepfner, W				
Fax: +49 30 25901 - 840		Telephone No. +49 30 2	25901-337			
<del></del>		l				

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

}

International application No. PCT/GB2004/000099

	Box No.	i Basis of the repo	rt			
1.	With reg filed, unl	Vith regard to the <b>language</b> , this report is based on the international application in the language in which it wa iled, unless otherwise indicated under this item.				
	whice	ch is the language of a nternational search (ui publication of the interr	nslations from the origin translation furnished for nder Rules 12.3 and 23. national application (und y examination (under Ru	1(b)) ler Rule 12.4)	,	
2. With regard to the <b>elements*</b> of the international application, this report is based on (replaceme have been furnished to the receiving Office in response to an invitation under Article 14 are referenced as "originally filed" and are not annexed to this report):					ent sheets which erred to in this	
	Descripti	ion, Pages				
	1-53		as originally filed			
	Claims, N	lumbers				
	1-13		as originally filed	•		
	□ a se	quence listing and/or a	ny related table(s) - see	e Supplemental Box Relating to Sequence	e Listing	
3.	<ul> <li>☐ The amendments have resulted in the cancellation of:</li> <li>☐ the description, pages</li> <li>☐ the claims, Nos.</li> <li>☐ the drawings, sheets/figs</li> <li>☐ the sequence listing (specify):</li> <li>☐ any table(s) related to sequence listing (specify):</li> </ul>					
4.	Supplem  th  th  th  th	peen made, since they ental Box (Rule 70.2(cone description, pages ne claims, Nos. ne drawings, sheets/figne sequence listing (sp	have been considered t )). s	ne amendments annexed to this report and to go beyond the disclosure as filed, as in the disc	nd listed below ndicated in the	
	* If i	tem 4 applies, s	ome or all of thes	se sheets may be marked "super	rseded "	

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000099

	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
1.	The	he questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- bvious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
	Ø	claims Nos. 9,10 (with respect to industrial applicability)				
		because:				
	☒	the said international application, or the said claims Nos. 9,10 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleon not comply with the technical re	ables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do omply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.			
		See separate sheet for further of	detai	ls .		

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-13

No: Claims

Inventive step (IS)

Yes: Claims

1-13

No: Claims

Industrial applicability (IA)

Yes: Claims

1-8,11-13

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

PCT/GB2004/000099

#### Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 9 and 10 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, the International Examination Authority fully concurs with the objection put forward by the International Search Authority and no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

#### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

D1: WO 02/094786 A (WALPOLE CHRISTOPHER; BROWN WILLIAM (CA); WEI ZHONGYONG (CA); ASTRAZEN) 28 November 2002 (2002-11-28)

#### Novelty

The document D1 discloses diarylmethylidene piperidine derivatives which structurally differ from the diarylmethylidene piperidine derivatives of present claim 1 in that they lack the carbonylamino group at position 3 of the right-hand phenyl residue (see page 1, lines 7, 8; page 2, formula I; page 5, line 17 - page 6, line 27).

Consequently, novelty has to be acknowledged for the subject-matter of the present independent claims 1 and 6-13 and the present dependent claims 2-5.

### Inventive step

The distinguishing feature between the novel subject-matter and D1 is the presence of a carbonylamino group at position 3 of the right-hand phenyl residue.

In the absence of any evidence for an unexpected technical effect linked to this feature, the objective problem underlying said subject-matter can merely be seen as the provision of further compounds useful for the provision of medicaments for the treatment of pain, anxiety and functional gastrointestinal disorders.

However, even in the absence of such a technical effect, the presence of inventive activity has to be acknowledged for the claimed solution to this very general problem, namely the modification of the compounds of D1 by exchanging the amino group at the right-hand phenyl moiety with an carbonylamino group, since this solution was not

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/000099

suggested by the prior art.

### Industrial applicability

There is no doubt that the subject-matter of the present claims 1-9 and 11-13 is industrially applicable.

However, for the assessment of the present claims 9 and 10 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.